Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
167.00    1.25 (0.74%)
Bid:
167.00
Ask:
171.50
Spread: 4.50 (2.695%)
Market Cap: £1.44b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Monday broker round-up UPDATE

Mon, 19th May 2014 07:55
Alent: Numis moves target price from 330p to 340p upgrading to add.AVEVA Group: Westhouse Securities initiates with a target price of 2260p and a buy recommendation.Bovis Homes Group: Deutsche Bank shifts target price from 1039p to 1042p and stays with its buy recommendation.Brown (N) Group: Jefferies cuts target price from 630p to 618p, while leaving its buy recommendation unchanged.Cello Group: N+1 Singer shifts target price from 122p to 126p and keeps a buy recommendation.Centaur Media: Westhouse Securities places both its target price (prev.: 77p) and its add recommendation under review.Darty: UBS lowers target price from 140p to 135p keeping a buy recommendation.Domino Printing Sciences: UBS upgrades from neutral to buy with a target price of 840p.Euromoney: N+1 Singer reduces target price from 1212p to 1190p retaining a hold recommendation.e2v technologies: Investec lowers target price from 225p to 215p, while leaving its buy recommendation unaltered.Grafton Group: Numis upgrades to buy with a target price of 750p.Hutchison China MediTech: UBS upgrades from neutral to buy with a target price of 1000p.InterContinental Hotels Group: Goldman Sachs raises target price from 2180p to 2410p and keeps its buy recommendation.Intertek Group: Goldman Sachs reduces target price from 3475p to 3325p maintaining a buy recommendation.ITE Group: Westhouse Securities moves target price from 206p to 216 and reiterates a neutral rating.Land Securities: Goldman Sachs cuts target price from 1158p to 1120p and downgrades to neutral.Morgan Advanced Materials: Jefferies lowers target price from 370p to 360p, while reiterating a buy recommendation.Petroceltic International: Westhouse Securities cuts target price from 275p to 250p retaining a buy recommendation.Phoenix IT Group: Westhouse Securities initiates with a target price of 128p and an add rating.Renishaw: UBS reduces target price from 1900p to 1700p, while its neutral rating is kept.Royal Bank of Scotland: Credit Suisse ups target price from 265p to 280p retaining an underperform rating.RSA Insurance: Berenberg ups target price from 463p to 491p and retains a hold recommendation.Shaftesbury: Liberum Capital moves target price from 665p to 680p maintaining a hold recommendation.Somero Enterprises: Canaccord Genuity takes target price from 124p to 134p and stays with its buy recommendation.StratMin Global Resources: Northland Capital initiates with a target price of 19.6p and a buy recommendation.WEIR Group: Liberum Capital starts with a target price of 2500p and a hold recommendation.Zotefoams: Investec raises target price from 185p to 300p, while leaving its add rating unchanged.

Related News

LONDON MARKET MIDDAY: FTSE 100 rises before ECB rate call; Halma sinks
12 hours ago

LONDON MARKET MIDDAY: FTSE 100 rises before ECB rate call; Halma sinks

(Alliance News) - Stock prices in London were higher at midday on Thursday, despite ongoing worries about a lack of progress on a Middle East peace de...

WINNERS & LOSERS: Halma sinks; Wizz Air omits guide but revenue climbs
14 hours ago

WINNERS & LOSERS: Halma sinks; Wizz Air omits guide but revenue climbs

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday.

Hutchmed News

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line
21 May 2026

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: AltynGold reports annual revenue surge
29 Apr 2026

EARNINGS AND TRADING: AltynGold reports annual revenue surge

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

Hutchmed begins phase-three trials of lymphoma therapy in China
23 Mar 2026

Hutchmed begins phase-three trials of lymphoma therapy in China

(Alliance News) - Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China.

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich
23 Mar 2026

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich

(Alliance News) - GSK makes regulatory progress in Japan for a cancer therapy, Anglo American moves to delist from the Swiss exchange as part of its r...

Hutchmed shares slide as recalls cancer treatment Tazverik
9 Mar 2026

Hutchmed shares slide as recalls cancer treatment Tazverik

(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen ...

Hutchmed China 2025 profit surges on divestment but revenue falls
5 Mar 2026

Hutchmed China 2025 profit surges on divestment but revenue falls

(Alliance News) - Hutchmed China Ltd on Thursday reported lower revenue for 2025, but reported sharply higher profit following a major divestment gain...

Hutchmed China shares rise as tumour treatment trial begins
4 Mar 2026

Hutchmed China shares rise as tumour treatment trial begins

(Alliance News) - Hutchmed China Ltd on Wednesday said it had launched a Phase I/IIa clinical trial of its cancer treatment HMPL-A580.